New York, December 19, 2023 - NRx Pharmaceuticals, Inc. (Nasdaq: NRXP) has been granted FDA clearance for its Investigational New Drug Application (IND) for NRX-101 for the treatment of complicated Urinary Tract infections (cUTI). The company’s shares surged 25% in trading on Monday following the news. https://prismmarketview.com/companies/nrx-pharmaceuticals-inc/ Complicated Urinary Tract Infections afflict approximately 3 million Americans each year, and pathogens have...